

**Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study**

Canuso CM, Singh JB, Fedgchin M, Alphs L, Lane R, Lim P, Pinter C, Hough D, Sanacora G, Manji H, Drevets WC.

Focus : journal of life long learning in psychiatry  
2019; 17(1):55-65

**ARTICLE IDENTIFIERS**

DOI: 10.1176/appi.focus.17105

PMID: 32015715

PMCID: PMC6996073

**JOURNAL IDENTIFIERS**

LCCN: 2002214614

pISSN: 1541-4094

eISSN: 1541-4108

OCLC ID: 50412933

CONS ID: not available

US National Library of Medicine ID: 101156081

This article was identified from a query of the SafetyLit database.